EQS-News

CureVac Announces Voting Results of Extraordinary General Meeting

Emittent / Herausgeber: CureVac / Schlagwort(e): Hauptversammlung CureVac Announces Voting Results of Extraordinary General Meeting 28.03.2023 / 22:05 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CureVac Announces Voting Results of Extraordinary General Meeting

 

TÜBINGEN, Germany / BOSTON, USA – March 28, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's extraordinary general meeting.

 

The shareholders of the Company voted in favor of all proposals. The proposals voted in favor for included the appointment of Dr. Alexander Zehnder as CEO effective April 1^st, 2023 and confirmation of the appointment of Dr. Myriam Mendila as CDO effective February 1^st, 2023.

A table containing tabulations of the votes casted is expected to be released in the coming days.

 

About CureVac

CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,000 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S. Further information can be found at www.curevac.com.